Clinical and biological evidence indicates that obesity may impair AI efficacy by increasing aromatase activity and altering drug metabolism, whereas tamoxifen remains largely unaffected. The gene discussed is CYP19A1; the disease is obesity due to melanocortin 4 receptor deficiency.